Nektar Therapeutics 2025 Q3 Earnings Narrows Loss, Beats Revenue Estimates by 11.42%

Nektar Therapeutics (NKTR) reported fiscal 2025 Q3 earnings on Nov 8, 2025, with a revenue decline and narrowed losses. The stock fell 13.8% weekly, but analysts remain bullish on its long-term potential.

Revenue

. , . The decline stemmed from the sale of its Huntsville manufacturing facility in late 2024, which eliminated product sales.

Earnings/Net Income

, . The EPS beat estimates, indicating stronger-than-expected cost management.

Post-Earnings Price Action Review

The strategy of buying NKTR when revenues exceed expectations and holding for 30 days shows potential. , and the Zacks Rank #2 (Buy) rating aligns with this approach. , bolstered by clinical updates on , including ACAAI 2025 data. However, biotech risks, such as clinical setbacks, remain.

Additional News

Nektar presented rezpegaldesleukin data at ACAAI 2025, highlighting its potential in and alopecia areata. The FDA granted Fast Track designation for alopecia areata treatment in July 2025. In October, , surpassing prior guidance.

CEO Commentary

CEO Howard W. Robin emphasized progress in rezpegaldesleukin’s development, noting its differentiated Treg mechanism and recent clinical data. He highlighted the Nobel Committee’s recognition of the drug’s mechanism and plans to advance it into Phase III trials. Robin underscored the importance of managing costs and extending the cash runway to support long-term development.

Guidance

Nektar expects to present top-line data from the REZOLVE-AA study in December 2025 and aims to initiate Phase III trials in atopic dermatitis after an FDA meeting. The company anticipates a cash runway through Q2 2027, , respectively.

Image Rule